tiprankstipranks
Ligand reports Q4 adjusted EPS $1.36, consensus $1.19
The Fly

Ligand reports Q4 adjusted EPS $1.36, consensus $1.19

Reports Q4 revenue $50.4M, consensus $46.64M. "2022 was a transformative year for Ligand, both operationally and financially. Following Ligand’s spin out of OmniAb, we believe we are well positioned to achieve significant revenue growth coupled with a lean cost structure," said Todd Davis, CEO of Ligand. "As we look to 2023 and beyond, we anticipate important clinical and regulatory events from our partners, along with the continued expansion of our portfolio through a focus on life sciences royalty opportunities."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on LGND:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles